David Quinn
, Clinical Professor of Medicine · University of Southern California/Los Angeles General Medical Center
Credentials: · · · · ·
History
1992–1995- 1990–1992
Medical Oncology
- 1987–1990
- 1983–1987
Doctor of Medicine
Research
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine · 2017 · 2,802 citations
The Lancet · 2017 · 1,812 citations
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Nature · 2018 · 645 citations
- TD
61 papers
36 papers
- NV
33 papers
26 papers
- IT
24 papers · 6 as a resident
23 papers
23 papers
22 papers
Grants
- 2014–2025
NCTN - Network Lead Academic Participating Site: USC
National Cancer Institute · UG1
PI · $1.3M · University of Southern California
- 2014–2019
NCI NCTN- Network Lead Academic Participating Site: USC
National Cancer Institute · U10
PI · $3M · University of Southern California
- 2006–2010
University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $3M · University of Southern California
- 2004–2009
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $298.3K · University of Southern California
Clinical trials
- 2018–2027
Principal investigator · Active not recruiting · Phase 2
University of Southern California
- 2016–2021
Principal investigator · Terminated · Phase 1
University of Southern California
- 2011–2017
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
Principal investigator · Terminated · Phase 2
University of Southern California
- 2009–2025
Short-Term Fasting: Impact on Toxicity
Principal investigator · Terminated
University of Southern California